
Neoleukin Therapeutics NLTX
Quartalsbericht 2025-Q3
hinzugefügt 13.11.2025
Neoleukin Therapeutics Langfristiger Schuldenstrom 2011-2026 | NLTX
Langfristiger Schuldenstrom Jährlich Neoleukin Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.56 M | 678 K | 1.17 M | 659 K | 556 K | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 2.56 M | 556 K | 1.12 M |
Langfristiger Schuldenstrom anderer Aktien in der Arzneimittelhersteller
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
5.36 M | - | 7.5 % | $ 6.35 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.05 | -3.24 % | $ 113 M | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Evolus
EOLS
|
2.53 M | $ 5.74 | 2.59 % | $ 370 M | ||
|
Evoke Pharma
EVOK
|
13.4 K | - | - | $ 36.6 M | ||
|
China Pharma Holdings
CPHI
|
39.3 K | $ 0.54 | -7.57 % | $ 9.43 M | ||
|
DURECT Corporation
DRRX
|
1.38 M | - | - | $ 50.1 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
357 K | $ 3.54 | -3.54 % | $ 49.8 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
3.91 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Harrow Health
HROW
|
887 K | $ 36.19 | -7.73 % | $ 1.33 B | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.51 | -3.84 % | $ 86.3 M | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 8.49 | -3.19 % | $ 435 M | ||
|
Jupiter Wellness
JUPW
|
213 K | - | - | $ 33.6 M | ||
|
Assertio Holdings
ASRT
|
928 K | $ 11.96 | -0.89 % | $ 850 M | ||
|
Bausch Health Companies
BHC
|
61 M | $ 5.56 | -1.24 % | $ 2.03 B | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.46 | 4.68 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
4.27 M | $ 2.89 | 0.52 % | $ 381 M | ||
|
Sundial Growers
SNDL
|
34.3 M | $ 1.52 | -1.3 % | $ 3.37 M | ||
|
Perrigo Company plc
PRGO
|
25.7 M | $ 11.22 | -4.06 % | $ 1.55 B | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
TherapeuticsMD
TXMD
|
1.47 M | $ 2.24 | 3.86 % | $ 23.4 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
Rockwell Medical
RMTI
|
1.38 M | $ 0.88 | -0.91 % | $ 20.5 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 22.78 | -0.35 % | $ 1.05 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
SCYNEXIS
SCYX
|
483 K | $ 0.76 | -2.49 % | $ 37.9 M | ||
|
Solid Biosciences
SLDB
|
1.79 M | $ 5.62 | -8.55 % | $ 229 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 2.66 | -5.0 % | $ 3.3 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
2.47 M | $ 7.07 | -3.15 % | $ 4.37 B | ||
|
Veru
VERU
|
1.07 M | $ 2.53 | 0.8 % | $ 341 M | ||
|
Viatris
VTRS
|
80.6 M | $ 14.58 | -0.92 % | $ 17.5 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
cbdMD
YCBD
|
98.7 K | $ 0.69 | -10.34 % | $ 2.98 M |